Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1057 results about "Targeting therapy" patented technology

Targeted therapy is a cancer treatment that uses drugs. But it is different from traditional chemotherapy, which also uses drugs to treat cancer. Targeted therapy works by targeting the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Protein three-mode and multi-feature fusion-based drug target affinity prediction algorithm

The invention provides a drug target affinity prediction algorithm based on protein three-mode and multi-feature fusion, and the algorithm makes full use of sequence information and two-dimensional and three-dimensional structural features of drugs and proteins, and realizes deep integration of data. The technical innovation point lies in that a multi-modal data fusion mechanism and an advanced graph neural network technology are introduced, and the sensitivity and recognition capability of the model to key biomarkers are enhanced through a dynamic attention mechanism. According to the technical advantage, the method has higher accuracy and stability when processing complex biological data, and compared with the prior art, the generalization ability and the interpretability are remarkably improved. In the aspect of technical maturity, the algorithm has passed multiple rounds of verification and shows good prediction performance and adaptability. The method is simple in operation and wide in market application prospect, can assist in new drug discovery and accelerate the drug design process, can also promote the development of the precision medical field, and particularly has important value in targeted therapy and disease prevention strategy formulation.
Owner:HUNAN NORMAL UNIVERSITY

Macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.
Owner:MACAU UNIV OF SCI & TECH

Inflammation-targeting bionic extracellular vesicle as well as preparation method and application thereof

The invention discloses an inflammation-targeting bionic extracellular vesicle as well as a preparation method and application thereof, and particularly relates to the field of medicines. According to the invention, a new generation of aminoglycoside antibiotic teicoplanin (Teic), which is high in albumin binding rate and weak in intracellular antibacterial effect, is loaded on neutrophil-derived extracellular vesicles (NEV) with natural drug carrying capacity and inflammatory response chemotactic capacity to prepare the drug-loaded vesicles (Teic-NEV), wherein the new generation of aminoglycoside antibiotic teicoplanin (Teic) is used for loading the neutrophil-derived extracellular vesicles (NEV). The drug-loaded extracellular vesicle Teic-NEV can be used for targeted therapy of cells and tissues infected by MRSA (Methicillin-Resistant Staphylococcus Aureus). In vitro, the Teic (at) NEV can be used for destroying MRSA mature biological membranes and killing intracellular MRSA. According to the invention, the in-vivo and in-vitro biological safety of the TeicatNEV is evaluated. Therefore, the invention provides a certain theoretical basis for the application of NEV-based drug delivery in the field of intracellular bacteria treatment, and also provides a new treatment strategy for in-vivo targeted treatment.
Owner:ZHEJIANG UNIV

Ultrasonic response adhesion integrated hydrogel as well as preparation method and application thereof

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.
Owner:XI AN JIAOTONG UNIV

Skin targeted therapy laser control method and system based on dual-wavelength synergistic effect

The invention discloses a skin targeted therapy laser control method and system based on a dual-wavelength synergistic effect, and the method comprises the steps: collecting the real-time morphological characteristics and pigment distribution data of skin tissues through a multispectral imaging unit, and recognizing the optical characteristic parameters of a target treatment region; generating a dual-wavelength combination scheme through a dynamic wavelength selection algorithm based on the optical characteristic parameters and the tissue structure characteristics of the target treatment area; according to a dual-wavelength combination scheme, generating a synergistic laser sequence with a specific pulse interval and energy ratio; the synergistic laser sequence is converted into a driving signal, and a dual-wavelength laser is controlled to output composite laser; and laser output parameters are dynamically adjusted through real-time thermal diffusion monitoring and an optical feedback mechanism. By utilizing the embodiment of the invention, accurate and selective heat dissipation of skin target tissues can be realized, surrounding normal tissues are effectively protected, the treatment safety and effectiveness are improved, and side effects are reduced.
Owner:CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV

Diaryl methyl pyrimidine piperazine compound as well as preparation method, pharmaceutical composition and application thereof

The invention belongs to the technical field of chemistry, and particularly relates to a diaryl methyl pyrimidine piperazine compound as well as a preparation method, a pharmaceutical composition and application thereof. The structural formula of the diaryl methyl pyrimidine piperazine compound is shown as a formula I, and R is a substituted aromatic group. The preparation process is simple, the prepared diaryl methyl pyrimidine piperazine compound or the pharmaceutically acceptable salt thereof has the activity of efficiently inhibiting WDR5-MLL 1, and a targeted therapy scheme and novel, safe and efficient candidate drug molecules are provided for treating acute myeloid leukemia with WDR5-MLL fusion mutation. Experimental results show that the tumor inhibition rates of mouse tumor-bearing groups treated by the compounds 5c, 5k and 5l prepared by the invention are 79%, 85% and 75% respectively and are superior to those of a positive control group, and the compounds have good development prospects.
Owner:TIANJIN JIANGXIN ZHICHENG TECHNOLOGY CO LTD

Application of therapeutic target in preparation of drug for treating targeted therapy resistance of kidney cancer

The invention discloses an application of a therapeutic target spot in preparation of a drug for treating targeted therapy resistance of kidney cancer. The therapeutic target spot is SLC27A3. The SLC27A3 comprises an SLC27A3 gene and a coding sequence thereof, an expression product of the SLC27A3 gene and a coding sequence thereof, and the SLC27A3 gene and an active fragment or derivative of the expression product thereof; the nucleotide of the SLC27A3 is as shown in SEQ ID NO. 1. According to the invention, a therapeutic target SLC27A3 is knocked out or silenced, and a compound Parishin for resisting the SLC27A3 protein is provided, so that the resistance of renal clear cell carcinoma cells to the pezopanib is remarkably improved, and the sensitivity of renal carcinoma cells to the pezopanib is enhanced.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

Method for identifying effectiveness of Cas target spot by combining gene large model and ML

The invention discloses a method for identifying the effectiveness of a Cas target spot by combining a gene large model and ML, and belongs to the field of biotechnology and artificial intelligence. The method comprises the following steps: constructing a detection array of A types of combined sequences and targeted combined sequences, wherein the detection array is provided with A detection units; respectively adding a combined sequence into each detection unit, carrying out incubation reaction, obtaining a fluorescence value of each detection unit, and carrying out normalization processing; carrying out key feature extraction on each combined sequence by adopting a feature extraction model; constructing a label set and a training set, constructing an integrated model, and training by adopting the label set and the training set; forming a machine learning model by the feature extraction model and the trained integrated model; and combining the new target sequence and the PAM sequence into a to-be-analyzed combined sequence, inputting the to-be-analyzed combined sequence into the machine learning model to obtain a predicted fluorescence value, and judging the recognition capability of the Cas protein on the combined sequence based on the fluorescence value. The method can assist in targeted therapy detection.
Owner:ZHEJIANG LAB

Modified CAIX targeting cyclic peptide, nuclide marker and application of modified CAIX targeting cyclic peptide in tumor diagnosis and treatment

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.
Owner:WUHAN HEMING PHARMACEUTICAL TECHNOLOGY CO LTD

Brain-targeted nano preparation loaded with ergosterol as well as preparation method and application of brain-targeted nano preparation

The invention provides an ergosterol-loaded brain-targeted nano preparation and a preparation method and application thereof, and relates to the field of nano materials and nano biological medicine.The active ingredient ergosterol of the nano preparation is entrapped in a DSPE-PEG-pinacol borate nano material, and the nano material has the ROS response characteristic and can be used for preparing a brain-targeted nano preparation. The ergosterol-loaded nano preparation is in the shape of a regular sphere, is uniform in particle size, has good dispersibility and stability, has good ability of targeted therapy of cerebral arterial thrombosis diseases, effectively solves the problems of poor targeting property, low bioavailability and the like of common drugs, enhances the therapeutic effect of ergosterol on cerebral arterial thrombosis, and has good application prospects. The ergosterol can effectively improve brain injury caused by the cerebral arterial thrombosis and has a good treatment effect, meanwhile, the ergosterol serving as the active ingredient plays a role in treating the cerebral arterial thrombosis by activating a PI3K / AKT / mTOR pathway, and a new direction is provided for treatment of the cerebral arterial thrombosis.
Owner:XUZHOU KEJIYUAN BIOTECHNOLOGY CO LTD

Novel compound and preparation method therefor

PCT designated stage expiredWO2024253475A1Organic active ingredientsGroup 5/15 element organic compoundsCombination drug therapyPharmaceutical Substances
The present invention relates to a novel anoctamin 1 (ANO1) inhibitory compound and has been completed by confirming that the novel compound may inhibit brain tumor by inhibiting the expression or activity of ANO1 which is a calcium-dependent chloride channel. Thus, according to the present invention, a novel compound usable as an ANO1 inhibitor may be provided. In addition, the compound of the present invention may simultaneously inhibit ANO1 and EGFR in brain tumor cells, and thus may be used as a dual-target anticancer agent for ANO1 and EGFR, and may also be used as a combined preparation for EGFR-targeted therapy, and thus is expected to be usable in various ways in the field of brain tumor prevention and treatment.
Owner:ASTRION INC

Engineering membrane coated nano drug delivery system and application thereof

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Leukemia targeted therapy preparation as well as preparation method and application thereof

The invention discloses a leukemia targeted therapy preparation as well as a preparation method and application thereof. Comprising a DNA nanoflower carrier targeting leukemia cells through a PTK7 receptor and benzene arsenic oxide loaded on the carrier. The DNA nanoflower carrier is obtained by rolling circle amplification, and a nucleic acid aptamer complementary sequence of targeted binding leukemia cells is introduced into a template chain subjected to rolling circle amplification. The preparation method comprises the following steps: modifying sulfydryl onto a DNA nanoflower by using DNA-Dithiol, then breaking a disulfide bond by using reduced glutathione to expose the sulfydryl, and loading benzene arsenic oxide onto the DNA nanoflower through a reaction between trivalent arsenic and the sulfydryl. The structure of the DNA nanoflower has a high surface area and high porosity, and can load a large amount of PAO, so that the killing performance on cancer cells is enhanced; the aptamer sgc8 sequence is introduced into the DNA nanoflower, so that the targeting of the DNA nanoflower to cancer cells is effectively realized; the preparation also has the advantages of being good in thermodynamic stability, easy to store, excellent in biocompatibility and the like, and has a very good application prospect.
Owner:HUNAN UNIV +1

Biological material for repairing ovarian function as well as preparation method and application of biological material

The invention provides a biological material for repairing an ovarian function as well as a preparation method and application thereof, and relates to the technical field of biological materials, a large number of experiments prove that specific biological protein components for reversing the ovarian function in extracellular vesicles are growth differentiation factor 9 (GDF-9) for repairing an ovary, and the biological material has the advantages that the ovarian repairing function mechanism of the specific biological protein components for reversing the ovarian function in the extracellular vesicles is found; according to the present invention, the GDF-9 extracellular vesicles (GDF-9Over-existed Extracellular vesicles, GOEs) are adopted as the active substance, such that the component is effectively extracted and purified so as to achieve the target of targeted therapy.
Owner:BEIJING HOSPITAL +1

Mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as preparation method and application of mesenchymal stem cell membrane bionic nano-enzyme

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.
Owner:JIANGYIN PEOPLES HOSPITAL +1

Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer

PCT designated stage expiredWO2024238486A2Organic active ingredientsAntineoplastic agentsStage tumorCD8
Described herein is the combination of STING / TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4 / 6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.
Owner:UNIV OF MASSACHUSETTS

Oral monoclonal antibody micro-coated nano-polysaccharide microsphere preparation for targeted therapy of inflammatory bowel disease and preparation method of oral monoclonal antibody micro-coated nano-polysaccharide microsphere preparation

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.
Owner:NORTHEAST NORMAL UNIVERSITY

Molecular switch for controlling transformation of colorectal cancer cell genome from MSS to MSI, inhibitor and application thereof

The invention provides a molecular switch for controlling a colorectal cancer cell genome to be converted from MSS to MSI, and belongs to the technical field of biology, and the molecular switch comprises TEAD protein or YAP / TAZ-TEAD complex protein. By inhibiting the molecular switch or inactivating the molecular switch, microsatellite instability of colorectal cancer cells can be induced, so that the curative effect of colorectal cancer immune targeted therapy is improved, and a new choice is provided for treatment of colorectal cancer. The invention further provides a molecular switch inhibitor for controlling the colorectal cancer cell genome to be converted from MSS to MSI and application of the molecular switch inhibitor.
Owner:YUNNAN UNIV

Preparation method and application of CD70 specific nano antibody molecular imaging probe

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Antibody drug conjugate property prediction method based on multi-modal fusion

The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.
Owner:LUDONG UNIVERSITY

Prodrug structure with ROS signal response performance and preparation method and application thereof

The invention relates to the field of biological medicine, in particular to a prodrug structure with ROS signal response performance and a preparation method and application thereof. The prodrug molecule with ROS signal response performance developed by the invention can quickly release living active molecules in a disease signal ROS-enriched environment, and plays a role in targeted therapy. The method has good universality, prodrug modification can be carried out on multiple molecules, four kinds of drug molecules approved to appear on the market are included, and it is verified that the solubility and biocompatibility of drugs can be improved, cytotoxicity can be reduced, and the effect of targeted therapy can be improved. Based on the structural characteristics of the molecules, the molecules can also be complexed with PVA hydrogel, and responsive controllable release of the medicine is further achieved.
Owner:UNIVERSITY OF HEALTH & REHABILITATION SCIENCES

Mouse EGFR (Epidermal Growth Factor Receptor) mutant lung adenocarcinoma cell line (EP Mus musculus) as well as preparation and application thereof

The invention relates to the technical field of medicines and biology, in particular to a mouse EGFR (Epidermal Growth Factor Receptor) mutant lung adenocarcinoma cell line (EP Mus musculus) as well as preparation and application thereof. The invention provides an EP cell line ([EGFRE19delta (mutation); trp53 (deletion), EP] is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common EGFRE19del mutation in lung adenocarcinoma, is a first lung adenocarcinoma mouse cell line carrying EGFR mutation known in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 strain mouse, and fills the blank of the mouse EGFR mutant cell line. The cell line provided by the invention has the background of EGFRE19del homozygous activation mutation and Trp53 homozygous deletion mutation, is sensitive to EGFR-TKI targeted therapy, can be used for in-situ tumor formation in subcutaneous and lung of an immune normal mouse C57BL / 6, and is suitable for immunotherapy and targeted therapy research of EGFR mutation lung adenocarcinoma.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Application of apparent modified nucleoside in tumor treatment

ActiveCN119015298Aachieve specific killing effectAchieve tumor killing effectOrganic active ingredientsAntineoplastic agentsAcute myeloid leukemiasPharmaceutical drug
The invention provides application of apparent modified nucleoside in tumor treatment, and belongs to the technical field of biological medicine. The invention provides an application of apparent modified nucleoside in preparation of a medicine for treating tumors. The apparent modified nucleoside comprises 5-formyl cytidine (5fdC), 5-hydroxymethyl cytidine (5hmdC) and 5-hydroxymethyl uridine (5hmdU). The invention provides that apparent modified nucleosides have different proliferation inhibition effects on different acute myelogenous leukemia cells. The high-expression CDA in the acute myelogenous leukemia tumor cells can effectively convert the apparent modified nucleoside 5fdC into 5fdU with toxic effect, so that the specific killing effect of the apparent modified nucleoside on the acute myelogenous leukemia tumor cells is achieved, and targeted therapy is realized. Therefore, the invention also provides a targeting drug for inhibiting CDA high-expression acute myelogenous leukemia cells.
Owner:GUIZHOU MEDICAL UNIV

Local micro-scale cooling control optimization method

The present invention relates to a local micro-scale cooling control optimization method and belongs to the field of biomedical engineering. In the method, the accurate cooling of a therapy region is realized by means of accurately controlling the release of a cryogenic medium. A micro-flow pump and a solenoid control valve are used to accurately adjust the flow and speed of the cryogenic medium, and a temperature sensor built in a probe is used to monitor the temperature of the therapy region in real time. The method further comprises a proportional-integral-derivative (PID)-based control algorithm, which dynamically adjusts the release of the cryogenic medium on the basis of real-time temperature data, so as to maintain a target therapy temperature. In addition, in the method, non-contact temperature monitoring is performed on the therapy region by means of an infrared camera, and data occurring during a therapy process is recorded, thereby optimizing a therapy effect. The technology provides a safe and accurate local cryotherapy method, which is applicable to medical therapy for dermatosis, muscle injury, inflammation, etc.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

Modified extracellular vesicles that specifically target kidneys and methods of preparation and applications thereof

The present invention discloses a method for the preparation and application of modified extracellular vesicles specifically targeted to the kidneys. These modified extracellular vesicles are derived from fibroblastic reticular cells in the mesentery tissue and express anti-inflammatory proteins after being modified with anchor peptides. By combining the extracellular vesicles secreted from fibroblastic reticular cells in the mesentery tissue with anchor peptides, the present invention ensures the effective targeting of the exosomes to the kidneys. Additionally, through genetic engineering of fibroblastic reticular cells, the exosomes secreted by these cells can carry the target molecule, anti-inflammatory protein CD5L, achieving precise targeted therapy for the kidneys. This innovative treatment strategy holds promising potential for the treatment of sepsis-associated acute kidney injury, bringing positive impacts to patients' health.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV

Application of Fe3O4 nanoparticles in preparation of medicine for treating benign prostatic hyperplasia

The invention provides application of Fe3O4 nanoparticles in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. The invention further discloses application of the Fe3O4 nano-particles in preparation of a medicine for treating benign prostatic hyperplasia. The research result of the invention emphasizes that the ferroferric oxide nanoparticles are a promising candidate drug for targeted therapy of BPH and related prostate diseases, and new possibility is provided for treatment intervention of urinary surgery. The inventor studies the effect of the Fe3O4 nanoparticles in inhibiting benign prostatic hyperplasia. Results of the inventor show that the nanoparticles not only effectively reduce the proliferation rate of prostate cells, but also improve related biochemical indexes. Therefore, the polypeptide has potential application in treatment of prostatic hyperplasia.
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Hepatocellular carcinoma gene knockout target library based on multiple omics and screening method thereof

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.
Owner:SHENZHEN EDDIE BAKER BIOTECHNOLOGY CO LTD

Nano-enzyme drug delivery system for targeted therapy of inflammatory bowel disease as well as preparation method and application of nano-enzyme drug delivery system

The invention relates to the field of biomedical materials, in particular to a nano-enzyme drug delivery system for targeted therapy of inflammatory bowel diseases as well as a preparation method and application of the nano-enzyme drug delivery system, and the nano-enzyme drug delivery system comprises mesoporous nano-enzyme as well as a MyD88 inhibitor and a coating which are loaded in mesoporous channels of the mesoporous nano-enzyme. The medicine for treating the inflammatory bowel disease, provided by the invention, can realize effective treatment on colitis through oral administration, has a stronger immune regulation effect compared with independent INNA1605 or nano-enzyme, and has a synergistic treatment effect. Meanwhile, the delivery system improves accumulation and targeting of the INNA1605 in the colon, reduces concentration in plasma, and reduces liver metabolism burden and cardiotoxicity possibly caused by whole body exposure of the medicine, so that a better curative effect is obtained.
Owner:WUHAN YINGNUO PHARMACEUTICAL CO LTD

Special glove for experiencing chemotherapy hand-foot syndrome

The utility model discloses a pair of special gloves for experiencing chemotherapy of hand-foot syndromes. The glove comprises a glove body, the glove body comprises an outer silica gel layer and an inner interlayer, the interlayer comprises a heating layer and a water injection layer, and the palm face and / or the hand back face of the glove body are / is provided with at least one simulated skin patch replacement window. And pulse electrode plates are mounted at the fingertip parts, positioned on the palm surface, of five fingers of the glove body. The glove can simulate and experience one or more of skin toxicity reaction symptoms of the hand-foot syndrome, and as a health education auxiliary tool, the glove can help clinically improve the quality and effect of health education and help chemotherapy / targeted therapy patients to recognize and manage the hand-foot syndrome as early as possible so as to steadily pass through the treatment period. The glove not only can help a patient to really experience the symptom of the hand-foot syndrome caused by chemotherapy, but also can be used for warming and massaging the hand during chemotherapy.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Application of imatinib mesylate in preparation of targeted therapeutic drug for gastric signet ring cell carcinoma

The invention discloses an application of imatinib mesylate in preparation of a targeted therapeutic drug for gastric signet ring cell carcinoma. The imatinib mesylate has an obvious inhibition effect on the growth of six patients with the pathological type of gastric signet-ring cell carcinoma, the inhibition effect is more obvious along with the increase of the concentration, the concentration and dosage dependency relationship is shown, and the half inhibitory concentration (IC50) is obviously smaller than that of a positive control drug apatinib. The medicine can play a targeted therapeutic role on the gastric signet ring cell carcinoma, and is small in toxic and side effects, economical, practical and low in cost.
Owner:ZHONGKE BOLIN (LIAONING) BIOLOGICAL RESEARCH CO LTD